Retinal Physician

JAN-FEB 2017

Issue link: http://retinalphysician.epubxp.com/i/783300

Contents of this Issue

Navigation

Page 58 of 71

R E T I N A L P H Y S I C I A N | J U N E 2 0 1 3 57 57 R E T I N A L P H Y S I C I A N . C O M | J A N U A R Y / F E B R U A R Y 2 0 1 7 13. Karkhaneh R, Lashay A, Ahmadraji A. Cytomegalovirus retinitis in an immunocom- petent patient: A case report. J Curr Ophthalmol. 2016;28:93-95. 14. Shah AM, Foster CS, Freeman WR. Viral Retinitis Following Intravitreal Triam- cinolone Injection in Patients with Predisposing Medical Comorbidities. Am J Ophthalmol. 2010;149: 433-440. 15. Hoover DR, Peng Y, Saah A, et al. Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression. Arch Ophthalmol. 1996;114:821-827. 16. Holbrook JT, Jabs DA, Weinberg DV, et al; Studies of Ocular Complications of AIDS (SOCA) Research Group. Visual loss in patients with cytomegalovirus retinitis and acquired immunodeficiency syndrome before widespread availability of highly active antiretroviral therapy. Arch Ophthalmol. 2003;121:99-107. 17. Deayton JR, Wilson P, Sabin CA, et al. Changes in the natural history of cytomega- lovirus retinitis following the introduction of highly active antiretroviral therapy. AIDS. 2000;14:1163-70. 18. Skiest DJ, Chiller T, Chiller K, Park A, Keiser P. Protease inhibitor therapy is as- sociated with markedly prolonged time to relapse and improved survival in AIDS patients with cytomegalovirus retinitis. Int J STD AIDS. 2001;12:659-664. 19. Sugar EA, Jabs DA, Ahuja A, et al. Incidence of cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol. 2012;153:1016-1024. 20. Rao NA, Zhang J, Ishimoto S. Role of retinal vascular endothelial cells in develop- ment of CMV retinitis. Trans Am Ophthalmol Soc. 1998;96:111-123. 21. Pepose JS, Holland GN, Nestor MS, Cochran AJ, Foos RY. Acquired immune deficiency syndrome. Pathogenic mechanisms of ocular disease. Ophthalmol- ogy.1985;92:472-484. 22. Studies of ocular complications of AIDS. Foscarnet-ganciclovir cytomegalovirus retinitis trial: 1. Rationale, design, and methods. Control Clin Trials. 1992;13:22-39. 23. Combination foscarnet and ganciclovir therapy vs. monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS: The Cytomegalovirus Retreatment Trial. Arch Ophthalmol. 1996;114:23-33. 24. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: The HPMPC Peripheral Cytomegalovirus Retinitis Trial. A randomized, controlled trial. Ann Intern Med. 1997;126:264-274. 25. MSL-109 adjuvant therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: The Monoclonal Antibody Cytomegalovirus Retinitis Trial. Arch Ophthalmol. 1997;115:1528-1536. 26. Studies of Ocular Complications of AIDS Research Group (SOCA); AIDS Clinical Tri- als Group. The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunode- ficiency syndrome: The Ganciclovir Cidofovir CMV Retinitis Trial. Am J Ophthalmol. 2001;131:457-467. 27. Jabs DA, Van Natta ML, Kempen JH, et al; Studies of Ocular Complications of AIDS Research Group. Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol. 2002;133:48-61. 28. Jabs DA, Enger C, Dunn JP, Forman M, Hubbard L. Cytomegalovirus retinitis and viral resistance: 3. Culture results. Am J Ophthalmol. 1998;126:543-549. 29. Jabs DA, Martin BK, Forman MS, Ricks MO, the Cytomegalovirus Retinitis and Viral Resistance Research Group Cytomegalovirus (CMV) blood DNA load, CMV retinitis progression, and occurrence of resistant CMV in patients with CMV retinitis. J Infect Dis. 2005;192:640-649. 30. Foscarnet-ganciclovir CMV retinitis trial: 4. Visual outcomes. Ophthalmology. 1994;101:1250-1261. 31. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med. 1992;326:213-220. 32. Berenguer J, Mallolas J. Intravenous cidofovir for compassionate use in AIDS patients with cytomegalovirus retinitis. Spanish Cidofovir Study Group. Clin Infect Dis. 2000;30:182-184. 33. Lalezari JP, Stagg RJ, Kuppermann BD, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann Intern Med. 1997;126:257-263. 34. Lalezari JP, Holland GN, Kramer F, et al. Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalo- virus retinitis in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:339-344. 35. Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med. 2002;346:1119- 1126. 36. Cvetkovic RS, Wellington K. Valganciclovir: a review of its use in the manage- ment of CMV infection and disease in immunocompromised patients. Drugs. 2005;65:859-878. 37. Mahadevia PJ, Gebo KA, Pettit K, Dunn JP, Covington MT. The epidemiology, treat- ment patterns, and costs of cytomegalovirus retinitis in the post-haart era among a national managed-care population. J Acquir Immune Defic Syndr. 2004;36:972- 977. 38. Perez-Olmeda M, Garcia-Perez J, Mateos E, et al. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication. J Med Virol. 2009;81:211-216. 39. Delaney WE 4th, Yang H, Miller MD, Gibbs CS, Xiong S. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother. 2004;48:3702-3710. 40. Jacobson MA, Wilson S, Stanley H, Cherrington J, Safrin S. Phase I study of com- bination therapy with intravenous cidofovir and oral ganciclovir for cytomegalovirus retinitis in patients with AIDS. Clin Infect Dis. 1999;28:528-533. 41. Henry K, Cantrill H, Fletcher C, Chinnock BJ, Balfour HH Jr. Use of intravitreal ganciclovir for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol. 1987;103:17-23. 42. Young SH, Morlet N, Heery S, Hollows FC, Coroneo MT. High dose intravitreal gan- ciclovir in the treatment of cytomegalovirus retinitis. Med J Aust. 1992;157:370- 373. 43. Cochereau-Massin I, Lehoang P, Lautier-Frau M, et al. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology. 1991;98: 1348-1353. 44. Diaz-Llopis M, Chipont E, Sanchez, et al. Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome. Am J Ophthalmol. 1992;114:742-747. 45.. Lieberman RM, Orellana J, Melton RC. Efficacy of intravitreous foscarnet in a patient with AIDS. N Engl J Med. 2004;330:868-869. 46. Diaz-Llopis M, Espana E, Munoz G, EspaƱa E, Navea A, Menezo JL. High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS. Br J Ophthalmol. 1994;78:120-124. 47. Rahhal FM, Arevalo JF, Munguia D, et al. Intravitreal cidofovir for the maintenance treatment of cytomegalovirus retinitis. Ophthalmology. 1996;103:1078-1083. 48. Kupperman B, Wolitz R, Stagg R, et al. A phase II randomized, double-masked study of intraocular cidofovir for relapsing cytomegalovirus retinitis in patients with AIDS. Paper presented at: Vitreous Society Annual Meeting; Cancun, Mexico; December 8-12,1996. 49. Musch DC, Martin DF, Gordon JF, Davis MD, Kuppermann BD. Treatment of cyto- megalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group. N Engl J Med. 1997;337:83-90. 50. Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained release ganciclovir implant. A randomized controlled clini- cal trial. Arch Ophthalmol. 1994;112:1531-1539. 51. Wan WB, Beadle JR, Hartline C, et al. Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro. Antimicrob Agents Chemother. 2005;49:656-662. 52. Ciesla SL, Trahan J, Wan WB, et al. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res. 2003;59:163-171. 53. Trofe J, Pote L, Wade E, Blumberg E, Bloom RD. Maribavir: A Novel Antiviral Agent with Activity Against Cytomegalovirus. Ann Pharmacotherap. 2008;42:1447-1457. 54. Reefschlaeger J, Bender W, Hallenberger S, et al. Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): In vitro and in vivo antiviral activity and mechanism of action. J Antimicrob Chemother. 2001;48:757-767. 55. Lischka P, Hewlett G, Wunberg T, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother. 2010;54:1290-1297. 56. Chon WJ, Kadambi PV, Xu Chang, et al. Use of leflunomide in renal transplant recipients with ganciclovir-resistant/refractory cytomegalovirus infection: A case series from the University of Chicago. Case Rep Nephrol Dial. 2015;5: 96-105. 57. Rifkin LM, Minkus CL, Pursell K, Jumroendararasame C1, Goldstein DA1. Utility of Leflunomide in the Treatment of Drug Resistant Cytomegalovirus Retinitis. Ocul Immunol Inflamm. 2015;11:1-4. 58. Whitcup SM, Fortin E, Lindblad AS, et al. Discontinuation of anticytomegalovi- rus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA. 1999;282:1633-1637. 59. Jabs DA, Bolton SG, Dunn JP, Palestine AG. Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy. Am J Ophthalmol. 1998;126:817-822. 60. Holbrook JT, Colvin R, van Natta ML, et al; Studies of Ocular Complications of AIDS (SOCA) Research Group. Evaluation of the United States public health service guidelines for discontinuation of anticytomegalovirus therapy after immune recov- ery in patients with cytomegalovirus retinitis. Am J Ophthalmol. 2011;152:628- 637. 61. Long-term follow-up of patients with AIDS treated with parenteral cidofovir for cytomegalovirus retinitis: the HPMPC Peripheral Cytomegalovirus Retinitis Trial. AIDS 2000;14:1571-1581.

Articles in this issue

Archives of this issue

view archives of Retinal Physician - JAN-FEB 2017